Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Debt / NOTE 0.250% 3/0
-
Market price (% of par)
-
108.02%
-
Total 13F principal
-
$23,831,000
-
Principal change
-
-$96,089,000
-
Total reported market value
-
$25,744,460
-
Number of holders
-
16
-
Value change
-
-$105,814,310
-
Number of buys
-
7
-
Number of sells
-
8
Institutional Holders of HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 as of Q4 2025
As of 31 Dec 2025,
HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 was held by
16 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$23,831,000
in principal (par value) of the bond.
The largest 10 bondholders included
Calamos Advisors LLC, MACKAY SHIELDS LLC, ADVENT CAPITAL MANAGEMENT /DE/, PIER 88 INVESTMENT PARTNERS LLC, Jefferies Financial Group Inc., SSI INVESTMENT MANAGEMENT LLC, FLOSSBACH VON STORCH SE, Universal- Beteiligungs- und Servicegesellschaft mbH, Calamos Wealth Management LLC, and OPPENHEIMER ASSET MANAGEMENT INC..
This page lists
16
institutional bondholders reporting positions
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.